---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211929"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:58:50.770879+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Definium Therapeutics Q1 2026: cash $373.4M; three Phase 3 readouts for DT120 ODT expected in coming months

## Summary
- Cash and investments $373.4M as of March 31, 2026; expected to fund operations into 2028.
- R&D expenses $41.5M (up $18.1M YoY) driven by DT120 ODT program costs; G&A $17.7M (up $8.9M).
- Three Phase 3 topline data readouts for DT120 ODT anticipated: Emerge (MDD) late Q2 2026, Voyage (GAD) early Q3, Panorama (GAD) late Q3.
- DT120 ODT program expanded into PTSD; Phase 3 Haven study expected to initiate in 2027 with ~200 patients.
- Ascend (MDD) trial first patient dosing expected Q2 2026; enrollment complete in Emerge and Voyage.

## SEC filing metadata
- accession: 0001193125-26-211929
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312526211929/0001193125-26-211929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312526211929/dftx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211929
- JSON: https://secwatch.observer/filing/0001193125-26-211929.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211929.txt

## Source-grounded claims
- claim_id: 6896bd549762f44239a8b542b375b5a448ac4c72
  claim: Definium Therapeutics, Inc. reported financial results for fiscal quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, Definium Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal quarter ended March 31, 2026, as well as information regarding a conference call to discuss these financial results and the Company’s recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000119312526211929/0001193125-26-211929-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.